Mounjaro results: what you can realistically expect

What the trial numbers actually tell you

SURMOUNT-1 is the landmark evidence for Mounjaro in weight management. Over 72 weeks, participants receiving 15 mg tirzepatide lost around 20–21% of starting body weight on average, with around a third of participants losing 25% or more. The 10 mg group averaged roughly 19%, and even the 5 mg group showed meaningful losses. These are averages across thousands of adults, some lost considerably more, some less. Averages, by definition, sit in the middle.

It's worth knowing what "average" includes: people who missed doses, people who tolerated only the lower doses, people who didn't fully change their diet. Participants who adhered closely to both the medicine and the lifestyle programme tended to sit above the mean. If you want a quick reality check on where you might land, tracking your starting weight precisely before the first pen is a habit that takes under a minute and makes your four-week and eight-week comparisons far more meaningful. For a closer look at how weight changes unfold week by week, our Mounjaro one-week results page covers what the early period typically looks like.

One more number worth noting: in the SURMOUNT-5 head-to-head trial, published in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks. That trial involved adults with obesity and no diabetes, it's the most direct comparison available and informed NICE's appraisal of tirzepatide (TA1026).

Why results differ between people taking the same medicine

The dose reached matters a great deal. Treatment starts at 2.5 mg, that dose exists to let your body adjust, not to drive weight loss. The prescriber titrates upward, typically every four weeks, toward the dose that balances effectiveness with tolerability. People who reach 15 mg and stay there consistently tend to produce the strongest Mounjaro UK results. Those who stay at lower doses because of side effects see less weight loss, and that's a clinically reasonable trade-off, not a failure.

Lifestyle factors sit alongside the medicine, not beneath it. The SURMOUNT programme paired tirzepatide with a structured reduced-calorie diet and increased physical activity. In practice, patients who prioritise protein adequacy, manage the GI side effects early rather than letting them disrupt eating habits, and build some form of regular activity into their week generally report better outcomes. Your prescriber can guide that balance. Mounjaro weight-loss results by dose and time period are covered in more detail if you want the granular breakdown.

Sex, starting weight, age, metabolic health, and whether type 2 diabetes is present all influence how much weight any individual loses. Men tend to start from a higher baseline weight, which can make percentage and absolute losses look different, our Mounjaro results for men page covers that specifically. Results of Mounjaro for people with type 2 diabetes are also documented across the SURPASS programme, though the licensed weight-management evidence base is distinct.

The timeline: when results tend to arrive

Most people notice very little change in the first week or two. That's not a sign the medicine isn't working, it reflects the slow titration design. The timeline from first dose to noticeable results is longer than most people expect going in. Four weeks in, on 2.5 mg, weight loss is often modest; by the end of the first month, many people have lost between one and three kilograms. By eight weeks (usually on 5 mg) the appetite-reducing effect becomes more consistent, and the rate of loss often picks up. The steepest average monthly losses in the trials appeared between roughly weeks 12 and 36, when doses are typically in the mid-to-upper range.

Beyond 36 weeks the rate of loss slows as the body approaches a new set point, and the focus shifts to maintaining what's been lost. Stopping treatment without a plan risks regain, the appetite-regulating effect of the medicine is part of what sustains the result, and this is something to discuss frankly with your prescriber before starting. A look at eight-week outcomes can give you a useful mid-term reference point as you go.

Making the decision: what to weigh up before you start

The evidence is strong. But the right question isn't "does Mounjaro produce results", it's "am I a good candidate, and am I set up for this to work?" Licensed eligibility covers adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or prediabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone doesn't determine suitability, a prescriber considers your full picture.

The cost of private treatment is real, and it's worth understanding what a legitimate price includes before comparing figures. Our weight-loss treatments page sets out what's covered at nume: consultation, prescription, medicine, and next-working-day tracked delivery, with no subscription and clinical re-review before every repeat. If you're weighing up options more broadly, the weight-loss treatment overview covers the licensed landscape, and our FAQs address the questions prescribers hear most often. If tirzepatide is something you're seriously considering, a free consultation with one of our GPhC-registered prescribers is the logical next step, they can tell you whether it makes clinical sense for you.